Algorae Pharmaceuticals (ASX:1AI) Net Change in Cash : A$-2.29 Mil (TTM As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Algorae Pharmaceuticals Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Algorae Pharmaceuticals's Net Change in Cash for the six months ended in Dec. 2023 was A$-1.47 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was A$-2.29 Mil.

Algorae Pharmaceuticals Net Change in Cash Historical Data

The historical data trend for Algorae Pharmaceuticals's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algorae Pharmaceuticals Net Change in Cash Chart

Algorae Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Net Change in Cash

Get a 7-Day Free Trial

-1.95

-1.94

-1.40

2.67

-0.13

Algorae Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Change in Cash	Get a 7-Day Free Trial															2.84	-0.17	-1.15	-0.83	-1.47

Algorae Pharmaceuticals Net Change in Cash Calculation

Algorae Pharmaceuticals's Net Change in Cash for the fiscal year that ended in Jun. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-1.986	+	0	+	1.85	+	0.008
	=	-0.13

Algorae Pharmaceuticals's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -1.009 + -0.977 + 0.521 + -0.001

= -1.47

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-2.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Algorae Pharmaceuticals Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Algorae Pharmaceuticals's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Algorae Pharmaceuticals (ASX:1AI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algorae Pharmaceuticals Ltd (ASX:1AI) » Definitions » Net Change in Cash

Comparable Companies

ASX:ATX ASX:CHM ASX:ACR ASX:PAB ASX:IMC ASX:NOX ASX:RAD ASX:BTC ASX:1AD ASX:TRP OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX

Traded in Other Exchanges

LVCLY:USA LVCLF:USA LHI0:Germany

Address

201 Sussex Street, Level 16, Tower 2, Darling Park, Sydney, NSW, AUS, 2000

Website

https://www.algoraepharma.com

Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for undermet medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. Its lead products comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. It is conceptualised to be a potential treatment for dementia, including Alzheimer's disease; NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.

Algorae Pharmaceuticals (ASX:1AI) Headlines

No Headlines